CytRx
Corporation (CYTR) is a biopharmaceutical company that develops and
commercializes innovative cancer therapies. The company's lead product
candidate, aldoxorubicin, is a tumor-targeted chemotherapy that is
designed to selectively deliver the drug to cancer cells while
minimizing damage to healthy tissue.
CytRx is also developing
other drug candidates, including INNO-206, a tumor-targeted version of
the chemotherapy drug doxorubicin, and its LADR (Linker Activated Drug
Release) platform technology, which is designed to improve the
delivery of cancer drugs.
CytRx was founded in 1985 and is
headquartered in Los Angeles, California. Tthe company was facing some
challenges related to the clinical development of its lead product
candidate, aldoxorubicin. The company had experienced some setbacks in
its clinical trials, which had led to delays in the development and
commercialization of the drug. The company's revenue for the fiscal
year 2020 was $3.3 million, representing a decrease from $5.7 million
in the previous year. Net loss for the same period was $14.1 million,
a decline from a net loss of $13.3 million in the previous year.
CytRx has a market capitalization of approximately $25 million as
of my knowledge cutoff of September 2021, and its stock is listed on
the OTC Pink market under the ticker symbol CYTR.
The
biopharmaceutical industry is subject to various risks, including
regulatory risks, competitive risks, and clinical trial risks.
However, CytRx's focus on developing innovative cancer therapies and
its efforts to address its clinical development challenges should
position it for improved performance in
|
